vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $57.3M, roughly 1.4× RHYTHM PHARMACEUTICALS, INC.). AMERISAFE INC runs the higher net margin — 10.2% vs -83.0%, a 93.1% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 10.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 2.8%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
AMSF vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $57.3M |
| Net Profit | $8.1M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 10.2% | -83.0% |
| Revenue YoY | 10.3% | 36.9% |
| Net Profit YoY | -9.0% | -9.6% |
| EPS (diluted) | $0.43 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $57.3M | ||
| Q3 25 | $82.0M | $51.3M | ||
| Q2 25 | $81.1M | $48.5M | ||
| Q1 25 | $72.6M | $32.7M | ||
| Q4 24 | $74.0M | $41.8M | ||
| Q3 24 | $78.7M | $33.3M | ||
| Q2 24 | $75.8M | $29.1M |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | $-47.5M | ||
| Q3 25 | $13.8M | $-52.9M | ||
| Q2 25 | $14.0M | $-46.6M | ||
| Q1 25 | $8.9M | $-49.5M | ||
| Q4 24 | $13.2M | $-43.3M | ||
| Q3 24 | $14.3M | $-43.6M | ||
| Q2 24 | $11.0M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | -82.2% | ||
| Q3 25 | 21.3% | -102.6% | ||
| Q2 25 | 21.5% | -93.4% | ||
| Q1 25 | 15.5% | -143.7% | ||
| Q4 24 | 22.7% | -98.6% | ||
| Q3 24 | 22.6% | -132.0% | ||
| Q2 24 | 18.1% | -139.2% |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | -83.0% | ||
| Q3 25 | 16.9% | -103.1% | ||
| Q2 25 | 17.2% | -96.1% | ||
| Q1 25 | 12.3% | -151.4% | ||
| Q4 24 | 17.8% | -103.6% | ||
| Q3 24 | 18.2% | -131.2% | ||
| Q2 24 | 14.5% | -110.9% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | $-0.73 | ||
| Q3 25 | $0.72 | $-0.82 | ||
| Q2 25 | $0.73 | $-0.75 | ||
| Q1 25 | $0.47 | $-0.81 | ||
| Q4 24 | $0.69 | $-0.71 | ||
| Q3 24 | $0.75 | $-0.73 | ||
| Q2 24 | $0.57 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $139.1M |
| Total Assets | — | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $388.9M | ||
| Q3 25 | $54.7M | $416.1M | ||
| Q2 25 | $48.5M | $291.0M | ||
| Q1 25 | $44.8M | $314.5M | ||
| Q4 24 | $44.1M | $320.6M | ||
| Q3 24 | $63.7M | $298.4M | ||
| Q2 24 | $30.6M | $319.1M |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $139.1M | ||
| Q3 25 | $274.8M | $148.8M | ||
| Q2 25 | $265.6M | $-11.9M | ||
| Q1 25 | $260.8M | $18.9M | ||
| Q4 24 | $257.3M | $21.7M | ||
| Q3 24 | $314.4M | $11.2M | ||
| Q2 24 | $301.0M | $39.3M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $480.2M | ||
| Q3 25 | $1.2B | $506.9M | ||
| Q2 25 | $1.2B | $372.7M | ||
| Q1 25 | $1.2B | $386.7M | ||
| Q4 24 | $1.2B | $392.3M | ||
| Q3 24 | $1.3B | $363.6M | ||
| Q2 24 | $1.2B | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $-25.4M | ||
| Q3 25 | $10.7M | $-26.6M | ||
| Q2 25 | $-8.4M | $-23.3M | ||
| Q1 25 | $-1.8M | $-40.4M | ||
| Q4 24 | $24.2M | $-18.8M | ||
| Q3 24 | $8.4M | $-25.2M | ||
| Q2 24 | $-2.6M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | — | ||
| Q3 25 | $9.8M | — | ||
| Q2 25 | $-9.5M | — | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $23.4M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | -11.7% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -3.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
